Design and synthesis of thiazole-5-hydroxamic acids as novel histone deacetylase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 21, 2007, Pages 5995-5999

  Anandan, Sampath Kumar ^a   Ward, John S ^a   Brokx, Richard D ^a   Denny, Trisha ^a   Bray, Mark R ^a   Patel, Dinesh V ^a   Xiao, Xiao Yi ^a  

^a EntreMed Inc Canada   (Canada)

Author keywords

Antiproliferative; HDAC; Inhibitors; Synthesis

Indexed keywords

4 METHYLPHENYLSULFONAMIDE DERIVATIVE; CHELATING AGENT; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; PIPERAZINE DERIVATIVE; SULFONAMIDE; THIAZOLE 5 HYDROXAMIC ACID DERIVATIVE; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; ZINC DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CHELATION; DRUG DESIGN; DRUG POTENCY; DRUG SYNTHESIS; ENZYME INHIBITION; HELA CELL; HUMAN; HUMAN CELL; IC 50; INHIBITION KINETICS; METAL BINDING; STRUCTURE ACTIVITY RELATION;

DRUG DESIGN; ENZYME INHIBITORS; HELA CELLS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34548853387     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.07.050     Document Type: Article

References (26)

1. Marks P.A., Rifkind R.A., Richon V.M., Breslow R., Miller T., and Kelly W.K. Nat. Rev. Cancer 1 (2001) 194
2. Kelly W.K., O'Connor O.A., and Marks P.A. Expert Opin. Invest. Drugs 11 (2002) 1695
3. Marks P.A., Richon V.M., Miller T., and Kelly W.K. Adv. Cancer Res. 91 (2004) 137
4. Bolden J.E., Peart M.J., and Johnstone R.W. Nat. Rev. Drug Discov. 5 (2006) 769
5. Curtin M.L. Expert Opin. Ther. Pat. 12 (2002) 1375
6. Hess-Stumpp H. Eur. J. Cell Biol. 84 (2005) 109
7. Kelly W.K., and Marks P.A. Nat. Clin. Pract. Oncol. 2 (2005) 150
8. Kelly W.K., O'Connor O.A., Krug L.M., Chiao J.H., Heaney M., Curley T., MacGregore-Cortelli B., Tong W., Secrist J.P., Schwartz L., Richardson S., Chu E., Olgac S., Marks P.A., Scher H., and Richon V.M. J. Clin. Oncol. 23 (2005) 3923
9. Remiszewski S.W., Sambucetti L.C., Bair K.W., Bontempo J., Cesarz D., Chandramouli N., Chen R., Cheung M., Cornell-Kennon S., Dean K., Diamantidis G., France D., Green M.A., Howell K.L., Kashi R., Kwon P., Lassota P., Martin M.S., Mou Y., Perez L.B., Sharma S., Smith T., Sorensen E., Taplin F., Trogani N., Versace R., Walker H., Weltchek-Engler S., Wood A., Wu A., and Atadja P. J. Med. Chem. 46 (2003) 4609
10. George P., Bali P., Annavarapu S., Scuto A., Fiskus W., Guo F., Sigua C., Sondarva G., Moscinski L., Atadja P., and Bhalla K. Blood 105 (2005) 1768
11. Catley L., Weisberg E., Kiziltepe T., Tai Y.T., Hideshimi T., Neri P., Tassone P., Atadja P., Chauhuan D., Munshi N.C., and Anderson K.C. Blood 108 (2006) 3441
12. Giles F., Fischer T., Cortes J., Garcia-Manero G., Beck J., Ravandi F., Masson E., Rae P., Laird G., Sharma S., Kantarjian H., Dugan M., Albitar M., and Bhalla K. Clin. Cancer Res. 12 (2006) 4628
13. Plumb J.A., Finn P.W., Williams R.J., Bandara M.J., Romero M.R., Watkins C.J., La Thangue N.B., and Brown R. Mol. Cancer Ther. 2 (2003) 721
14. Qian X., LaRochelle W.J., Ara G., Wu F., Petersen K.D., Thougaard A., Sehested M., Lichenstein H.S., and Jeffers M. Mol. Cancer Ther. 5 (2006) 2086
15. Suzuki T., Ando T., Tsuchiya K., Fukazawa N., and Saito A. J. Med. Chem. 42 (1999) 3001
16. Ryan Q.C., Headlee D., Acharya M., Sparreboom A., Trepel J.B., Ye J., Figg W.D., Hwang K., Chung E.J., Murgo A., Melillo G., Elsayed Y., Monga M., Kalnitskiy M., Zwiebel J., and Sausville E.A. J. Clin. Oncol. 23 (2005) 3912
17. Furumai R., Matsuyama A., Kohashi N., Lee K.-H., Nishiyama M., Nakajima H., Tanaka A., Komatsu Y., Nishino N., Yoshida M., and Horinouchi S. Cancer Res. 62 (2002) 4916
18. Finnin M.S., Donigian J.R., Cohen A., Richon V.M., Rifkind R.A., Marks P.A., Breslow R., and Pavletich N.P. Nature 401 (1999) 188
19. Somoza J.R., Skene R.J., Katz B.A., Mol C., Ho J.D., Jennings A.J., Luong C., Arvai A., Buggy J.J., Chi E., Tang J., Sang B.C., Verner E., Wynands R., Leahy E.M., Dougan D.R., Snell G., Navre M., Knuth M.W., Swanson R.V., McRee D.E., and Tari L.W. Structure 12 (2004) 1325
20. Vannini A., Volpari C., Filocamo G., Casavola E.C., Brunetti M., Renzoni D., Chakravarty P., Paolini C., De Francesco R., Gallinari P., Steinkuhler C., and Di Marco S. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 15064
21. Mai A., Massa S., Rango R., Cerbara I., Jesacher F., Loidl P., and Brosch G. J. Med. Chem. 46 (2003) 512
22. Angibaud P., Arts J., Emelen K.V., Poncelet V., Pilatte I., Roux B., Brandt S.V., Verdonck M., Winter H.D., Holte P.T., Marien A., Floren W., Janssens B., Dun J.V., Aerts A., Gompel J.G., Gaurrand S., Queguiner L., Argoullon J.-M., Hijfte L.V., Freyne E., and Janicot M. Eur. J. Med. Chem. 40 (2005) 597
23. Lavoie R., Bouchain G., Frechette S., Woo S.H., Khalil E.A., Leit S., Fournel M., Yan P.T., Trachy-Bourget M.-C., Beaulieu C., Li Z., Besterman J., and Delorme D. Bioorg. Med. Chem. Lett. 11 (2001) 2847
24. Shinji C., Nakamura T., Maeda S., Yoshida M., Hashimoto Y., and Miyachi H. Bioorg. Med. Chem. Lett. 15 (2005) 4427
25. In vitro fluorescent histone deacetylase assay: HDAC inhibition assays were performed using the HDAC fluorescent activity assay kit (Biomol Research Laboratories, Plymouth Meeting, PA). HeLa cell nuclear extract, which contains a number of HDAC isozymes and other nuclear factors, was used as the source of HDAC activity. The final substrate concentration in the assay mixture was 50 μM. The reaction was allowed to proceed for 10 min at room temperature before a stop solution was added. Test compounds were prepared as 20 mM stock solutions in DMSO (Molecular Biology grade, Sigma-Aldrich Co., St. Louis, MO) and stored at -70 °C. DMSO had no significant effect on the activity of this assay at concentrations up to 5% with the final DMSO concentration in the assays of no more than 2%. Assays were performed in white polystyrene 96-well half-area assay plates (Corning, Corning, NY) and measured on a Wallac 1420 fluorescent plate reader (Wallac Oy, Turku, Finland) with an excitation wavelength of 355 nm, an emission wavelength of 460 nm, and a one sec signal averaging time.
26. Mai A., Esposito M., Sbardella G., and Massa S.A. Org. Prep. Proced. Int. 33 (2001) 391